CHAPTER 235

Hemophilias and von Willebrand's Disease

Robin R. Hemphill

REFERENCES

1. Fijnvandraat K, Cnossen MH, Leebeek FW, Peters M: Diagnosis and management of haemophilia. *BMJ* 344: e2707, 2012. [PMID: 22551712]
2. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al: Guidelines for the management of hemophilia. *Haemophilia* 19: e1, 2013. [PMID: 22776238]
3. Budde U, Schneppenheim R: Von Willebrand factor and von Willebrand disease. *Rev Clin Exp Hematol* 5: 335, 2001. [PMID: 11844133]
4. Singleton TC, Keane M: Diagnostic and therapeutic challenges of intracranial hemorrhage in neonates with congenital hemophilia: a case report and review. *Ochsner J* 12: 249, 2012. [PMID: 23049462]
5. Kulkarni R, Soucie JM: Pediatric hemophilia: a review. *Semin Thromb Hemost* 37: 737, 2011. [PMID: 22187396]
6. Vanderhave KL, Caird MS, Hake M, et al: Musculoskeletal care of the hemophiliac patient. *J Am Acad Orthop Surg* 20: 553, 2012. [PMID: 22941798]
7. Keeling D, Tait C, Makris M: Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. *Haemophilia* 14: 671, 2008. [PMID: 18422612]
8. Berntorp E, Astermark J, Baghaei F, et al: Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment. *Haemophilia* 18: 158, 2012. [PMID: 22151198]
9. Mannucci PM, Gringeri A, Peyvandi F, et al: Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). *Haemophilia* 13(Suppl. 5): 65, 2007. [PMID: 18078400]
10. Gouw SC, van der Bom JG, Auerswald G, et al: Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. *Blood* 109: 4693, 2007. [PMID: 17218379]
11. Gouw SC, van der Bom JG, Ljung R, et al: Factor VIII products and inhibitor development in severe hemophilia A. *N Engl J Med* 368: 231, 2013. [PMID: 23323899]
12. Mannucci PM: Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better. *Blood Transfus* 8: 288, 2010. [PMID: 20967171]
13. Franchini M: Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: recombinant is better. *Blood Transfus* 8: 292, 2010. [PMID: 20967172]
14. http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=693 (National Hemophilia Foundation, Medical and Scientific Advisory Council: MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders; revised November 2012.) Accessed April 28, 2013.
15. Bjorkman S, Berntorp E: Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. *Clin Pharmacokinet* 40: 815, 2001. [PMID: 11735604]
16. Berntorp E, Bjorkman S: The pharmacokinetics of clotting factor therapy. *Haemophilia* 9: 353, 2003. [PMID: 12828668]
17. Forsyth AL, Zourikian N, Valentino LA, Rivard GE: The effect of cooling on coagulation and haemostasis: should "Ice" be part of treatment of acute haemarthrosis in haemophilia? *Haemophilia* 18: 843, 2012. [PMID: 22913708]
18. Schulman S: *Mild Hemophilia. Treatment of Hemophilia*. No 41. Montreal, Quebec, Canada: World Federation of Hemophilia, 2012.
19. Franchini M, Zaffanello M, Lippi G: The use of desmopressin in mild hemophilia A. *Blood Coagul Fibrinolysis* 21: 615, 2010. [PMID: 20829683]
20. Mannucci PM: *Desmopressin (DDAVP) in the Treatment of Bleeding Disorders. Treatment of Hemophilia*. Revised Edition. No 11. Montreal, Quebec, Canada: World Federation of Hemophilia, 2012.
21. Serernetis SV, Aledort LM: Desmopressin nasal spray for hemophilia A and type I von Willebrand disease. *Ann Intern Med* 126: 744, 1997. [PMID: 9139573]
22. Quon DV, Konkle BA: How we treat: haematuria in adults with haemophilia. *Haemophilia* 16: 683, 2010. [PMID: 20041958]
23. Ghosh K, Jijina F, Mohanty D: Haematuria and urolithiasis in patients with haemophilia. *Eur J Haematol* 70: 410, 2003. [PMID: 12756025]
24. Warrier I, Ewenstein BM, Koerper MA, et al: Factor IX inhibitors and anaphylaxis in hemophilia B. *J Pediatr Hematol Oncol* 19: 23, 1997. [PMID: 9065715]
25. Teitel J, Berntorp E, Collins P, et al: A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. *Haemophilia* 13: 256, 2007. [PMID: 17498074]
26. Iorio A, Matino D, D'Amico R, Makris M: Recombinant factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. *Cochrane Database Syst Rev* 8: CD004449, 2010. [PMID: 20687076]
27. Rodgers GM: Prothrombin complex concentrates in emergency bleeding disorders. *Am J Hematol* 87: 898, 2012. [PMID: 22648513]
28. Glangrande P: *Acquired Hemophilia. Treatment of Hemophilia.* Revised Edition. No 38. Montreal, Quebec, Canada: World Federation of Hemophilia, 2012.
29. Webert KE: Acquired hemophilia A. *Semin Thromb Hemost* 38: 735, 2012. [PMID: 22941793]
30. Shander A, Walsh C, Bailey H, Cromwell C: Acquired hemophilia presenting as profound hematuria: evaluation, diagnosis, and management of elusive cause of bleeding in the emergency department setting. *J Emerg Med* 45: e1, 2013. [PMID: 23643238]
31. Sborov DW, Rodgers GM: How I manage patients with acquired haemophilia A. *Br J Haematol* 161: 157, 2013. [PMID: 23373521]
32. Zeitler H, Goldmann G, Marquardt N, Ulrich-Merzenich G: Long term outcome of patients with acquired haemophilia—a monocentre interim analysis of 82 patients. *Atheroscler Suppl* 14: 223, 2013. [PMID: 23357169]
33. Seethala S, Gaur S, Enderton E, Corral J: Postpartum acquired hemophilia: a rare cause of postpartum hemorrhage. *Case Rep Hematol* 2013: 735715, 2013. [PMID: 23533849]
34. Federici AB, Mannucci PM: Advances in the genetics and treatment of von Willebrand disease. *Curr Opin Pediatr* 14: 23, 2002. [PMID: 11880730]
35. Mannucci PM, Federici AB: Management of inherited von Willebrand disease in 2007. *Ann Med* 39: 346, 2007. [PMID: 17701477]
36. James PD, Lillicrap D: von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies. *Am J Hematol* 87(Suppl. 1): S4, 2012. [PMID: 22389132]
37. Hassan MI, Saxena A, Ahmad F: Structure and function of von Willebrand factor. *Blood Coagul Fibrinolysis* 23: 11, 2012. [PMID: 22089939]
38. Nichols WL, Rick ME, Ortel TL, et al: Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. *Am J Hematol* 84: 366, 2009. [PMID: 19415721]
39. Nichols WL, Hultin MB, James AH, et al: von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). *Haemophilia* 14: 171, 2008. [PMID: 18315614]
40. Mannucci PM, Franchini M, Castaman G, Federici AB; Italian Association of Hemophilia Centers: Evidence-based recommendations on the treatment of von Willebrand disease in Italy. *Blood Transfus* 7: 117, 2006. [PMID: 19503633]
41. Castaman G: Treatment of von Willebrand disease with FVIII/VWF concentrates. *Blood Transfus* 9(Suppl. 2): s9, 2011. [PMID: 21839030]
42. Mannucci PM, Federici AB, James AH, Kessler CM: von Willebrand disease in the 21st century: current approaches and new challenges. *Haemophilia* 15: 1154, 2008. [PMID: 19624761]

USEFUL WEB RESOURCES

American Society of Hematology Clinical Guidelines—http://www.hematology.org/Practice/Guidelines/2934.aspx

British Committee for Standards in Haematology Guidelines (subcommittee of the British Society for Haematology)—http://www.bcshguidelines.com/

National Heart, Lung, and Blood Institute—http://www.nhlbi.nih.gov/health/indexpro.htm

National Hemophilia Foundation—http://www.hemophilia.org

World Federation of Hemophilia—http://www.wfh.org